ABSTRACT
BACKGROUND Genome sequencing of large three-generation families allows de novo mutations to be identified in the second generation, validated and phased in the third generation, and ultimately attributed to the first-generation germlines in which they arose. Because germline mutations accumulate with age, we hypothesized that they may limit the duration of childbearing in women, and if accompanied by accumulation of mutations in somatic tissues, reflect aging rates generally in both sexes. Here we test whether germ cell mutations present in a Generation I cohort when they were young adults predict two clinically important outcomes in those same individuals: survival in both sexes, and age-related fertility decline in women. We also explore a possible linkage between the timing of puberty and the establishment of adult germline mutation accumulation rates.
METHODS Germline mutation counts in 122 Generation I individuals (61 women, 61 men) from 41 three-generation Utah families were converted to germline mutation rates by normalizing each subject’s number of mutations to the callable fraction of their genome. Age at death, cause of death, cancer incidence, and reproductive histories were provided by the Utah Population Database, Utah Cancer Registry, and Utah Genetic Reference Project. Fertility analyses were restricted to the 53 women whose age at last birth (ALB) was at least 30 years, the approximate age when the decline in female fertility ending with menopause begins. The age when adult germline mutation accumulation rates are established was estimated by regression analyses of the Generation I data. Self-reported age at menarche was available for 20 of the Generation I women.
RESULTS After adjusting for birth year, sex, and parental age effects in Cox proportional hazard regression models, a one standard deviation increase in the germline mutation rates present in the Generation I cohort when they were young adults predicted significantly higher all-cause mortality (hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.12-3.46; p=0.019) in those same individuals. The median survival advantage for subjects with mutation rates < 25th percentile vs. those with mutation rates > 75th percentile was approximately 8 years for women and 13 years for men. Among women with ALB ≥ 30 years, those in the top 50% of germline mutation rates had significantly fewer live births than those in the bottom 25% (p=0.026), and higher mutation rates were significantly associated (p=0.036) with a younger ALB (<25th percentile, 34.8 years). Linear regression analyses indicate that the germline mutation accumulation rates of adulthood are established no earlier than middle to late childhood. We therefore investigated the hypothesis that puberty induces mutation accumulation after a prepubertal phase when mutation burdens are plateaued. As predicted, among Generation I women, those reporting older ages at menarche had significantly lower germline mutation rates. Furthermore, Generation II parental couples with similar germline mutation accumulation rates (mainly reflecting mutations accumulating in fathers) varied about five years in the paternal age at which they acquired the same number of mutations, as would be expected if puberty, which also has a range of onset of approximately 5 years, causes a resumption of mutation accumulation after a plateaued prepubertal phase.
CONCLUSIONS Germline mutation accumulation rates in healthy young adults may provide a measure of both reproductive and systemic aging. The data further suggest that mutation accumulation rates are established around puberty, just when DNA repair genes’ expression levels are known to begin their lifelong decline.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH R01AG038797 and R21AG054962 (to R.M.C.); University of Utah Program in Personalized Health (H.D.M.); NIH T32GM007464 (to T.A.S.); NIH R01AG022095 (to K.R.S.); NIH R01HG006693, R01HG009141, and R01GM124355 (to A.R.Q.); NIH GM118335 and GM059290 (to L.B.J.); NIH P30CA2014 (to the Utah Population Database, a.k.a. the UPDB); National Center for Research Resources Public Health Services grant M01RR00064 (to the Huntsman General Clinical Research Center at the University of Utah); and gifts from the W.M. Keck Foundation and the George S. and Delores Doré Eccles Foundation that supported the Utah Genetic Reference Project (UGRP). Sequencing of the CEPH samples was funded by the Utah Genome Project, the George S. and Dolores Doré Eccles Foundation, and the H.A. and Edna Benning Foundation. We thank the Pedigree and Population Resource of the Huntsman Cancer Institute, University of Utah (funded in part by the Huntsman Cancer Foundation) for its role in the ongoing record collection, maintenance and support of the UPDB; and additional support for the UPDB from the University of Utah, and the University of Utah’s Program in Personalized Health and Center for Clinical and Translational Science.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Most of the data analyzed in this manuscript are provided either within the manuscript itself, or in the manuscript posted by Sasani et al. on bioRxiv at https://www.biorxiv.org/content/10.1101/552117v2 and its accompanying links; additional data may be accessed by contacting the corresponding author (Dr. Cawthon).